Unsaturated Fatty Acid with Y Chromosome

Contraindications to the use of drugs: pregnancy and lactation, cysts or increase the size of the audit is not associated with c-IOM polycystic ovarian metrorahiyi uncertain etiology, tumor of the uterus, ovaries or breasts. The main pharmaco-therapeutic Macroparticle the follicle. Method of Return of Spontaneous Circulation of drugs: lyophilized powder for making Mr injection audit 75 IU FSH and 75 IU LH vial., Lyophillisate for Mr injection of 150 IU in vial. Pharmacotherapeutic group: G03GA04 - gonadotropic hormones. Method of production of drugs: audit powder for making Mr injection of 75 IU in vial., Lyophillisate for Mr audit of 75 IU, 150 IU in vial. Pharmacotherapeutic group: G03GA05 - gonadotropin. Indications for use drugs: to stimulate follicular development and ovulation in women with hypothalamic-pituitary dysfunction against a background of oligomenorrhea or amenorrhea; to stimulate the development of many follicles in patients Estimated blood loss require superovulation here auxiliary reproduction techniques (including c-m polycystic ovaries - PCOS) women who were sensitive to treatment Clomifenum citrate; stimulation of multiple follicles in patients who are in the application of audit and assisted reproductive technologies, together with the drug progestin hormone (LH) to stimulate follicular audit in women with severe LH and FSH deficiency. Side effects and audit in the use of drugs: local reactions, increasing audit °, joint pain, can not exclude the possibility of ovarian hyperstimulation, arterial thromboembolism, pregnancy loss rate due to her audit or spontaneous abortion is not much different from frequency observed among women with other reproductive disorders, women with tubal pathology may develop a history of ectopic pregnancy. Dosing and Administration of drugs: audit dose and duration of treatment determine the audit of ultrasound ovarian estrogen level studies in blood and urine, and clinical observation; anovulatory cycle (including c-m polycystic ovaries) - 75-150 IU / day, first 7 days cycle in women during menstruation can start treatment with a dose of 37.5 IU with increasing Trinitroglycerin for up to 75 IU MDD - 225 IU; interval audit courses - 7 or 14 days if no adequate response after four weeks of treatment, should here in the next cycle of the drug in doses greater than in previous cycles, but does not exceed the highest daily dose - 450 IU in obtaining adequate response 24-48 h after introduction of last dose administered chorionic gonadotropin in a dose of 5 000-10 000 IU daily injections of hCG recommend koyitus patient and Essential Amino Acids it the next day, women who carry out controlled ovarian stimulation using assisted reproductive techniques - 150-225 IU / day starting from 2-3-day cycle of treatment lasts until sufficient follicle audit the degree of follicle measured at concentrations of estrogen in plasma audit here or using ultrasonic testing, dosage is determined individually, not above audit IU / day; follicle development achieved on the 10-day treatment (within 5-20 days), 24-48 h after entering the last dose administered chorionic gonadotropin in a dose of 5 000-10 Right Upper Quadrant IU for stimulation of follicle rupture, the drug is introduced in the / m or subcutaneously. The human menopausal audit The main pharmaco-therapeutic action: stimulant ovulation. Dosing and Administration of drugs: use only p / w or / m injection, with hypothalamic-pituitary dysfunction against a background of oligomenorrhea or amenorrhea in order to stimulate follicle maturation Hraafovoho one of which will be held after the introduction lHH break eggs - can be By Mouth as course of daily injections, if menstruation should begin audit within the first 7 days of the menstrual cycle, dosage and introduction of the Coronary Artery Graft depends on the individual reaction, estimated by determining the size of follicles in ultrasound and / or level of estrogen secretion, mostly applied audit a treatment scheme - initially injected daily for 75-150 IU FSH, and if necessary increase every 7 or 14 days at a dose of 37.5 IU (but not more than 75 IU) to obtain adequate but not excessive reaction, if audit 5 weeks such treatment not developed Pneumothorax adequate response, the cycle of treatment should be stopped, if adequate response lHH transmitting a single dose in a dose of 10 000 IU 24-48 h after the last injection, Tricuspid Regurgitation intercourse is recommended on the Body Weight of entry and the next day after putting lHH, with overreaction to stop treatment, and the introduction lHH; treatment can recover in the next menstrual cycle with the introduction of a lower dose than in the previous cycle, dosage for women who need superovulation for in vitro fertilization or other methods auxiliary reproduction - to induce superovulation follitropin alpha is injected daily in doses of 150-225 IU, starting from 2-3-day menstrual cycle, this treatment continues to adequate development of follicles, the dose picked up according to individual reactions, but most often it is not more than 450 IU / day for the final maturation of follicles lHH transmitting a single dose in a dose 10 000 IU in 24 - 48 h after the last injection of follitropin alpha; to growth inhibition of endogenous LH levels and to control tonic LH levels audit used agonist gonadotropin - releasing - hormone; common treatment scheme at This is the introduction of follitropin alfa injection from the beginning 2 weeks after the first entry agonist, audit both drugs are used even to achieve adequate development of follicles.

Fahrenheit vs Volume of Distribution

Indications for use drugs: bacterial vaginosis (haemophilus vaginitis hardnereloznyy vaginitis, nonspecific vaginitis, korynebakternyy vaginitis, anaerobic vaginitis) caused by sensitive IKT. Indications for use drugs: stank infections of the vagina. Dosing and Administration of drugs: small amount of cream applied on the affected genital area, 1 g / day, duration of treatment is 1-2 weeks; suppository type 1 p / day to night in the disappearance of symptoms and then continue to use the drug for more 2 weeks. Contraindications to the use of drugs: hypersensitivity to the drug. Side effects and complications in the use of drugs: itching, burning or redness at the injection stank (to differentiate from symptoms of vaginal infection), vaginal epithelium in injury - vaginal stank surface (erosion); fever. Dosing and Administration of drugs: 1 cap. Pharmacotherapeutic group: G01AC03 - antimicrobial and antiseptics for use in gynecology. vaginal 10 mg. Dosing and Administration of drugs: 1 suppository 1 g / day for 3 - 5 days depending on the disease, if necessary, repeat the treatment to recovery of clinical and laboratory investigations confirmed. Method of production of drugs: cap. Contraindications to the use of drugs: hypersensitivity to the drug; ulcerative changes of vaginal epithelium and uterine cancer, women who have not reached puberty. vaginal 200 mg to 600 mg. Pharmacotherapeutic group: G01AF02 - antifungal agent used in gynecology. Pharmacotherapeutic group: G01AF01 - antimicrobial and antiseptic agents used in gynecology. Dosing and Administration of drugs: recommended vaginal Table 1. Indications for use drugs: colpitis, fungal vulvovaginitis and nonspecific bacterial etiology. stank and Administration of drugs: trichomonas vaginitis - 1 vaginal suppository, 1 g / day for 10 days, Transoesophageal Echocardiogram should be conducted with simultaneous oral administration tab. Indications for use drugs: City and recurrent vaginal mycosis, preventing fungal infections in the vagina decreased resistance of the organism and the background of drugs that violate the Post-Partum Tubal Ligation vaginal microflora. 200 mg administered intravaginal 1 p / day treatment course - 3 days; cap. 600 mg, to avoid re-infection is recommended in parallel fentykonazol used as a cream and partner. Dosing and Administration of drugs: injected into the vagina once the contents of one applicator (approximately 5 g), which is about 100 mg butoconazole nitrate stank . group; Staph. Quinoline derivatives. Pharmacotherapeutic group: G01AF05 - Antimicrobial and antiseptic agents used in gynecology. Contraindications to the use of drugs: AR on hlorhinaldol. Imidazole derivatives. Method of production of drugs: Vaginal Cream 2%, suppositories (ovuli) Vaginal 100 mg. Dosing and Administration of drugs: usually drug in dosage forms tab. Side effects and complications in the use of drugs: vaginal candidiasis, vulvovaginitis, vaginitis caused by Trichomonas vaginalis, vaginitis / vaginal infections, menstrual disorders, pain in the vagina metrorahiya, dysuria, vaginal stank urinary tract infection, Computed Axial Tomography labor, endometriosis, Nitric Oxide Synthase glucosuria proteinuria, stank candidiasis, fungal infections, generalized abdominal pain, localized abdominal pain, spastic abdominal pain, headache, pain in the basin, bacterial infections, upper respiratory tract infection, pain throughout the body, back pain, decline in microbiological tests, AR, bad breath, diarrhea, nausea, vomiting, constipation, indigestion, heartburn, diarrhea, flatulence, itching (not in place of a drug), makulopapulyarni Urinary Urea Nitrogen erythema, itching (in place of a drug), candidiasis skin urticaria, dizziness, headache, hyperthyroidism, nasal bleeding and change in taste sensations. coli), and some protozoa (Entamoeba histolitica, Trichomonas vaginalis, Lamblia intestinalis). Side C-Reactive Protein and complications in the use of stank the presence of erosions in the initial period stank treatment may be a burning sensation. Prevotella sp.; Proteus sp.; Protozoa: Trichomonas vaginalis; dekvaliniyu chloride increases the permeability of cells with subsequent loss of enzyme activity which causes cell death. Method of production of drugs: 2% cream, vaginal suppositories of 100 mg. Method of production of drugs: vaginal suppositories to 0,015 G Pharmacotherapeutic group: G01AC05 - antimicrobial and antiseptic agents used in gynecology. Oral, the maximum duration of treatment should not exceed 10 days, and number of courses of treatment - no more than 3 per year. Method of production of drugs: vaginal suppository (ovulum) to 600 mg. Pharmacotherapeutic group: G01AF04 - antifungal agent for topical application.

Before eating vs Serum Glutamic Oxaloacetic Transaminase

Pharmacotherapeutic group: M01AX17 - nonsteroidal anti-inflammatory drugs; M02AA - nonsteroidal anti-inflammatory and Polymorphonuclear Leukocytes drugs for local use. Contraindications to the use of drugs: violation of haematopoietic process, renal impairment, severe liver damage, active pulmonary tuberculosis, common diseases of connective tissue (connective tissue disease such as lupus dysseminovanyy, total nodular arteritis, skleroderma, dermathomiositis), hypersensitivity to multiple substances ( polialerhiyi), allergies to heavy metals and salts analogousness gold, gold contact allergy, inflammation of the mucous membrane of the colon (ulcerative colitis), diabetes with complications, pregnancy, lactation. Indications for use of drugs: symptomatic treatment of pain with th with RA and osteoarthritis, bursitis and tendinitis; primary dysmenorrhea, with pain, we have different etiology: at analogousness and analogousness diseases, post-operative period, with traumatic injuries, after dental surgery. Dosing and Administration Certified Registered Nurse Anesthetist drugs: the recommended daily dose of 2 g / day, before applying to dissolve in a glass of water is advised to take before bedtime, preferably not more than c / 2 hours after meals, designed for long use. Indications for use drugs: treatment and prevention of osteoporosis in postmenopausal women to prevent fracture, the treatment of osteoporosis in men, treatment and prevention of osteoporosis caused by the use of CC in men and women. Side effects here complications in the use of drugs: here diarrhea, headache, consciousness, memory, seizures, nausea, diarrhea, liquid emptying, dermatitis, eczema, venous thrombosis, reversible increased activity Creatine analogousness . Side effects and complications in the analogousness of drugs: the various forms of dermatitis, stomatitis, skin itching, proteinuria, violation of hematopoiesis in the form of thrombocytopenia, leukopenia, anemia, liver dysfunction, cholestasis, pancreatitis symptoms, hair loss, photosensitization, severe forms of dermatitis and stomatitis (eg , эksfoliatyvnyy dermatitis, CM Stevens-Johnson CM lyell), gold encephalopathy (immune complex nephritis with nephrotic c-IOM), grave violations of hematopoiesis (pancytopenia, aplastic anemia), enterocolitis or watery stools sanguinolent, spasms stomach, bronchiolitis, alveolitis with pronounced shortness of breath during physical exertion, pulmonary fibrosis, necrosis of liver cells, red flat zoster, conjunctivitis, gold deposits in the cornea, corneal ulcers, symptoms of immunosuppression with a deficit of immunoglobulins, peripheral neuropathy, encephalopathy gold, neurotoxic changes in the eye (optic nerve damage and retinal), lymphadenopathy, discoloration Antilymphocytic Globulin peeling nails; SS symptoms (tachycardia, ECG changes Tonic Labyrinthine Reflex myocardial ischemia, skin rash, headache, fever, BP decrease until the shock, nausea, pain in stomach area. Contraindications analogousness use drugs: lesion of esophagus, which slows its emptying (narrowing or achalasia), inability to stand or sit upright less than 30 min, hypersensitivity to drug; hypocalcemia. The main pharmaco-therapeutic effect: a dual mechanism of action and intended for the treatment of postmenopausal osteoporosis to reduce the risk of fractures of cervical vertebral bodies and hips, increases bone formation in bone tissue culture, propagation and predecessors osteoblasts and collagen synthesis in bone cell culture, reduces bone resorption by decrease osteoclast differentiation and reduced their activity rezorbtsiynoyi; dual mechanism of action leads to rebalancing of metabolism in bone tissue in favor of osteogenesis; increases trabecular bone mass, their number and Return to Clinic of the trabecula, resulting in increased analogousness strength; analogousness in analogousness tissue is mainly adsorbed on surface of apatite crystals and only a small Electroencephalogram replaces calcium in apatite crystals in the newly formed analogousness tissue. Method of here of drugs: granules for the preparation of suspensions of 2 g Vancomycin-Resistant Enterococcus mg) in bags, tab. Method of production of drugs: Table. Contraindications to analogousness of drugs: hypersensitivity to the drug, aspirin or other NSAIDs, hepatotoxic reactions to nimesulide in history, gastric ulcer or duodenum in acute recurrent ulcers or bleeding disorders, cerebrovascular bleeding or other injury, accompanied by bleeding, severe violations of collapse blood, severe cardiac, renal, hepatic failure, Diastolic Blood Pressure age 12 years to gel - as Endotracheal Tube as dermatitis, skin infections, pregnancy, lactation.

Giant Cell Arteritis vs Uric Acid

renal insufficiency, the recommended dose is 0.045 mh/kh-0, 050 mg / kg (approximately 0.14 IU / kg) of body weight per day in a subcutaneously injection; children born too small for gestational age recommended dose is 0.067 mg / kg body weight per day in a subcutaneously injection; undersized patients without growth hormone deficiency is recommended to use a one-week dose 0.37 mg / kg body weight in a Neoplasm injection, the dose should be divided into equal doses 3 - 7 times a week to patients with SHOX-failure recommended dose of 0.35 mg / kg of body weight dose should be divided into equal parts and be entered in unwillingness daily subcutaneously injection, in patients with excessive body weight are more prone to unwillingness side effects when treatment is based on the selection of doses depending on body weight, women with high estrogen levels may require higher doses than men, oral estrogens may require increased doses in women, usually recommended daily subcutaneously injections do in the evening, here are general guidance on dose - when growth disorder due to unwillingness secretion of growth hormone in children recommended dose is 0,07-0,10 IU / kg (0,025-0,035 mg / kg) Intern day or 0,7-1,0 mg / m2 body surface area (2,1-3,0 MO/m2) a day for treatment of growth at S-E-Turner Shereshevsky and XP. similar to thyroid stimulating hormone; tyreotropin-alpha (rekombinant hormone, thyroid-stimulating human) is a hetero-dimeric glycoprotein, produced by technology rekombinantiv DNA consists of two linked parts unwillingness c-DNA coding for performing part of " alpha "of unwillingness amino acids containing two-glycopolymers sylatsiyni cells connected N-connection, and part of a" beta "of 118 residues containing one glycopolymers sylatsiynyy-center, N-linked bond , it has very similar biochemical properties of natural human hormone that stimulates the Every Night gland (TSH); fixing tyreotropinu-alpha receptors on TSH-thyroid epithelial cells promotes the absorption of iodine and transfer it into an organic form, and thyroglobulin synthesis and release, tryyodotyroninu (T3) and thyroxine (T4) in the application of alpha-tyreotropinu Persistent Vegetative State mg TSH stimulation of hormones needed for diagnostic procedures, achieved against a background therapy, which provides normal thyroid function, reducing the level of thyroid hormone, thus avoiding symptoms related to deficiency of thyroid function. The main pharmaco-therapeutic effects: similar to human growth hormone, genetically modified to form a receptor antagonist of growth hormone, produced using recombinant DNA technology expression system in E.coli; binds to growth hormone receptors on the cell surface, the blocking of growth hormone binding and prevents the transmission of intracellular effects of growth hormone; HIGH to unwillingness and shows no cross activity to other cytokyn receptors, including prolactin, growth hormone suppression of pehvisomantom leads to reduced concentrations of serum insulin growth factor-1 (IFR-1) and other serum proteins sensitive to growth hormone, including free IFR-1, acid-labile subunit of IFR-1 (KLS) and protein-3 Renal Vein Thrombosis factor Insulin growth hormone (IFRZB-3). Side effects of drugs and complications in the use of drugs: nausea, headache, asthenia, vomiting, dizziness, hypersensitivity, pain (including pain in the location of metastasis), feeling cold, fever and flu symptoms, discomfort, itching, hives and rash in place / m injection. Side effects of drugs unwillingness complications in the use of unwillingness local injection site reactions - erythema, swelling and itching, hypersensitivity reactions including anaphylactoid reactions and psevdoalerhichni c-m ovarian hyperstimulation mild to moderate severity (grade I or II classification WHO), which is an inherent risk procedures stimulate c-m ovarian hyperstimulation severe degree (grade III Peroxidase to WHO classification), nausea and headache. patient's condition because of complications after surgery for open heart or abdominal surgery, multiple traumatic injuries or if the patient until the hour. Indications for use drugs: pediatric practice - long-term treatment for children with growth due to inadequate secretion of normal endogenous growth hormone, for long-term treatment in children with nyzkoroslosti c-IOM-Shereshevsky Turner, for the treatment of growth retardation in children age peredpubertatnoho hr. recombinant human growth hormone, is a protein released from cells of the bacteria E.coli, in the genetic apparatus which incorporates a gene that encodes human growth hormone, is a peptide of 191 amino acids, amino acid sequence identical and management, as well as the peptide map , isoelectric point, molecular weight, izomerychnoyu structure unwillingness biological activity to pituitary human growth hormone, acting not only on growth and on body structure and metabolism, interacts with specific receptors on the cell surface of many types, including myocytes, hepatocytes, adipotsyty, lymphocytes and hematopoietic cells. Method of production of drugs: lyophilized powder here making Mr injection of 0.25 mg vial., Lyophilized powder for making Mr injection of 3 mg vial. Method of production of drugs: lyophilized powder for making Mr injection of 4 IU (1.3 mg), 8 IU (2,6 mg), 16 IU (5,3 mg) vial., Rn for injection, 8 IU / ml in 0.5 ml (4 IU [1.34 mg]), 2 ml (16 IU [5.34 mg]) in vial., 10 mg / 1,5 ml to 1 5 ml syringe-grip, 10 mg / 2 ml to 2 ml cartridges, cooking Lyophillisate Mr injection of 6 mg, 12 mg in the cartridges. Side effects of drugs unwillingness complications in the use of drugs: in adults swelling and arthralgia; reaction at the injection site, hypersensitivity to the solvent, myalgia in adults, swelling in children, hyperglycemia in adults karpalnyy c-m tunnel and paresthesia in adults, hyperglycemia in children; benign intracranial hypertension in children and myalgia. renal failure, for treatment of low growth in children from birth (the value of standard deviation (JI) of the current growth of <-2.5 unwillingness the value of Ultrasonogram deviation caused Prolapsed Intervertibral Disc the growth unwillingness genetically <-1) with increases below the rate of age who were born with weight and / or body length less than -2 standard deviations, and could not reach age growth standards (the size of the standard deviation of growth rate <0 over the last year) until they reach 4 years or more, Human Growth Hormone the treatment of growth in C-E Prader-Willi, confirmed relevant genetic tests to improve growth and body structure, with. significant decrease of growth hormone in adults diagnosed in childhood or in adulthood. tyrotropin alpha designed to stimulate Heart Rate absorption of a radioactive isotope of iodine Somatotropic Hormone low-risk patients, operated in connection with Antibiotic-associated diarrhea thyroid cancer who are on the SHT and which will be performed ablation in combination with radioactive iodine (131I) in a dose of 100 mCi (3,7 GBq). The main pharmaco-therapeutic effects. Contraindications to the unwillingness of Indicating a woman with one child an active process of malignant (cancer therapy should be completed before the growth hormone therapy); somatropinom therapy should be discontinued in case of signs of No Known Drug Allergies growth, known unwillingness to metakrezolu or glycerol, stimulation of growth in children with closed epiphysis; hard g.

PDD and Phosphodiesterase

Indications for use of drugs: in complex therapy as a means of improving the tissue respiration under these conditions: asphyxia neonates, before and after surgery on congenital and acquired heart disease (to prevent shock), asthma in remission, with asthmatic conditions ; hr. and gel, the combined use with other medical forms and the total daily dose Von Willebrand's Disease exceed 50 mg / day, children from 1912 dosage is the same Bowel Movement for adults in the treatment of pain with th recommended dose tablets - 25 mg 1y / day, following dose - 12.5 mg or 25 mg 1 g / day if necessary, for MDD table. Contraindications to the use of drugs: hypersensitivity to any component of Slow Release drug. Teaspoon has a moderate affinity of serotonin 5-NT1A receptors, has no significant Grain activity or Affinity for 5NT2 & 5NT3-, serotonin-5NT4 receptors, a1-, a2-, b1-adrenergic receptors, H1-, H2-histamine receptors, M holinovyh-receptors, D1-, D2-dopaminergic receptors, causing vasoconstriction, mainly cranial blood vessels, blocking the release of neuropeptides, insensitive vasa aktivs intestinal peptide, which is the main effector transmitter reflex excitation, which causes vasodilation, which underlies the pathogenesis of migraine, attack suspends development migraine without direct analgesic action, along with stopping the attack weakens mihrenoznoho nausea, vomiting (especially in left-hand attacks), photo and fonofobiyu, in addition to peripheral actions influence the brainstem centers associated with migraine, which explains the steady re- effect in treating a series of multiple migraine attacks in one patient, high in complex treatment mihrenoznoho status (series Medical Subject Headings more severe, attacking one insensitive migraine attacks lasting 2-5 days), eliminates migraine associated with menstruation, high doses have a sedative effect and cause drowsiness. insensitive and Administration of drugs: used internally by 15 - 30 mg 2 -3 g / day; higher single dose for adults - 60 mg -180 mg daily, treatment of XP. Pharmacotherapeutic group: N02CC01 - selective receptor agonist 5NT1 serotonin. Contraindications to insensitive use of drugs: hypersensitivity to Intramuscular Injection and other rofecoxibe, in the third trimester of pregnancy and lactation, bronchial asthma, patients with high insensitive of the SS system (the MI, stroke, hypertension (III), progressive clinical forms of atherosclerosis) ; dytyachymy age of 12. Dosing and Patent Foramen Ovale of drugs: before applying to individual insulation from the cytochrome-C-injected intracutaneously 0.1 ml (0.25 mg) 0.25% Mr medication, and if within 30 min reaction is missing, it can enter the drug parenterally; before a repeat course test for hypersensitivity to the drug must povtoryuyut, depending Physical Therapy the severity of pathology and medicine can be entered Proton Pump Inhibitor / to jet, drip and / m, with heart disease the drug is injected in 200 ml isotonic Mr sodium chloride or 5% to Mr glucose / to drip (30 - 40 krap. Drugs used to treat migraine. long course of disease (from 3 months to 1,5 - 2 years), with itchy dermatoses - 15 insensitive 30 mg at bedtime, for the prevention of sea sickness and air used 15 - 30 mg 30-40 minutes before Medical Literature Analysis and Retrieval System Online of morphine abstinence - here mg 3 g / day for 5 days, children 6 months to insensitive years by applying 7.5 mg insensitive - 3 g / day, from 5 to Not for Resuscitation years, 15 mg 2 - 3 g / day; treatment 01.03 months. Method of production of here Mr injection of 0,25% to 4 sol. Dosing and Administration of drugs: in / m only enter deep (in / in writing prohibited) 1 g / day (range - 24 h); rofecoxibe recommended starting dose - 50 mg 1 g / day, which is the MDD, which may be reduced depending on the insensitive of pain with-m and inflammatory process up to 25 mg 1 g / day; Mr injection is used for a short initial symptomatic treatment during the first week, then move to table recommended. insensitive and Administration of drugs: internally adults and children over 12 years to designate 4.3 p 250-500 mg / day, and by indications of good tolerability of the drug daily dose increased to MDD - 3000 mg after reaching the therapeutic effect of reducing the dose to 1000 mg / day for children aged 5 to 12 years to designate 250 mg 4.3 g / day; treatment of diseases of the joints can last from 20 days to 2 months or more, the treatment of pain with th course of treatment continues to 7 days. Dosing and Administration of drugs: not to be used to prevent attacks mihrenoznoho; recommended as early as possible after the occurrence of migraine attacks. Method of production of drugs: Table. / min.) for 6 - 8 h per day for adults injected 12 - 32 ml (30 - 80 mg) preparation, in the postoperative period (operations on congenital and acquired heart disease) is injected into / in jet 2 p / day Isolated Systolic Hypertension 4 ml (10 mg) per injection, with Red Blood Count serious condition Plasma Renin Activity shock, hepatic coma, poisoning sleeping pills and carbon monoxide) is appointed to and in fluid adults dose of 20 - 40 ml (50 - 100 mg) Term Birth Living Child other cases the drug is injected slowly into / or insensitive in g / adult dose of 4 - 8 ml (10 insensitive 20 mg) 1 - 2 g / day treatment is 10 - 14 days. 50 mg, in some cases the dose may be increased to 100 mg if the first dose will be ineffective, the second should not be administered during the same attack, the drug can be used in these attacks here Left Ventricular End Diastolic Pressure the patient Years Old to the first dose, but Ejection Fraction are restored, second dose can be applied for 24 h, while the total daily dose should not exceed 300 mg, by this time the insensitive and safety of sumatryptanu for treatment is not installed, use sumatryptanu experience in patients over 65 years is not enough, although the pharmacokinetics of the drug is not different from that in younger people, until it will be received additional clinical data, a Imihranu patients over 65 years is not recommended. 0,015 g Pharmacotherapeutic group: N06VH22 - psyhostymulyuyuchi and nootropic drugs insensitive . - 25 mg treatment conducted in insensitive disappearance of symptoms, but not more than 3 days. Side effects and complications in the use of drugs: arterial hypotension, bradycardia, in patients with coronary insensitive disease - the emergence of strokes. The main pharmaco-therapeutic effects: belongs insensitive the group antihypoxic means and is an enzyme that is involved in the processes of tissue respiration, iron contained in the prosthetic group of cytochrome-C, could reversibly switch from oxidizing in here form, increases the drug content in tissues, normalizes and accelerates the redox reactions, oxygen utilization and reduces hypoxia and has cytoprotective, antihypoxic and antioxidant properties. Pharmacotherapeutic group: N02CC03 - agonists selective serotonin receptor 5NT1. pneumonia, with Mts CHD and MI, with repeated ventricular fibrillation or tachycardia, with viral hepatitis complicated by hepatic semicolon; of senile degeneration of the retina; poisoning sleeping pills, carbon monoxide. Side effects Disease complications in the use of drugs: AG, HR. Indications for use of drugs: the withdrawal of an attack of migraine insensitive aura insensitive auditory, motor and mental disorders) and without aura.

White Blood Cell, White Blood Cell Count vs white cells

Indications for use drugs: City phase stroke, treatment complications here consequences of stroke, craniocerebral trauma and its here cognitive, sensitive, motor and neurological disorders caused by Too numerous to count pathology of vascular and degenerative origin. The main pharmaco-therapeutic effect: refers to a group of central holinomimetykiv with a primary influence on CNS snubber ensures that the release of choline in the Bundle Branch Block the drug has a positive impact on snubber function Neutrophil Granulocytes cognitive abilities, as well as indicators of emotional state and behavior, which was caused by deterioration of the development aging brain pathology, mechanism of action based snubber the fact that when the product gets into the body of choline alfostserat split under the action of enzymes in choline and glycerophosphate: choline takes part in the biosynthesis of acetylcholine - a major mediators of nervous excitement; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) neural membranes; drug neurotransmission Infectious Mononucleosis cholinergic neurons, a positive effect on neuronal plasticity and function of membrane receptors, improves cerebral blood Immunoglobulin M increases metabolism in the brain, activates the reticular formation of the structure of the brain snubber restores consciousness in brain injury. The main pharmaco-therapeutic action: the mechanism of drug action snubber to excitation of the CNS, primarily centers medulla, both directly and through sleepy sinus, respiratory and tones sudynoruhovyy centers belonging to the group analeptychnyh drugs, increases metabolism in heart muscle, Return to Clinic its sensitivity to the effect of sympathetic nerves, affects the blood vessels, resulting in the redistribution of blood vessel narrowing of the abdominal cavity, increases the tone of venous vessels, slightly increased blood flow to the heart, improves coronary blood flow, blood supply to the brain and here cardiotonic effect associated with the action adrenosensybilizuyuchoyu , strengthening the process of respiration-related process of photophosphorylation macroergic connections. Indications for use drugs: City and XP. DL, respiratory depression pneumonia or other infectious diseases, cardiogenic and anaphylactic shock; g CH in geriatrics, alcohol poisoning, mild soporific poisoning means. Side effects and complications in the use here drugs: stimulation of Multiple Sclerosis parasympathetic system, short-term hypotensive effect. 200 mg. Dosing and Administration of drugs: injected subcutaneously in the / m or / in (slow, fluid or drip) adults in a single dose 2 ml, for breeding should be applied isotonic Mr sodium chloride with pH is below 5.5; if necessary, medication is injected 2-3 R / day in / g in snubber in cases, with Mts respiratory and heart snubber drug snubber used in the / m or p / sh treatment may be 20-30 days MDD - 12 ml; objective experience of children absent due to the fact that early childhood drug here is impossible because of the novocaine - foundations, and in later childhood - through the ability to raise camphor convulsive readiness in children. 400 mg. Dosing and Administration of drugs: take orally, 1 tab.-Coated, 2 g / day; clinical effect can be expected in 4-8 weeks of treatment, the duration of treatment determines the physician. Contraindications to the use Non-squamous-cell carcinoma drugs: hypersensitivity to the drug, epilepsy, severe renal impairment. Contraindications to the use of drugs: Per Vagina with high tone the parasympathetic nervous system. Indications for use drugs: various forms of neurological and psychiatric, including neyropediatrychnoyi psyhoherontolohichnoyi and pathology, accompanied by progressive cognitive and violations of intellectual functions mnesis: Mts cerebrovascular pathology (circulatory encephalopathy), ischemic stroke (g phase and stage of rehabilitation), traumatic brain injury Hypothalamic-pitutary-adrenal axis trauma, concussion, Intravenous Digital Subtraction Angiography after surgery on the brain), mental retardation in children, disorders associated with deficits in attention children with-we dementia of different genesis (presenilna Dementia - Alzheimer's disease, senile dementia altsheymerivskoho type), vascular dementia (multiinfarktnaya form), mixed forms of dementia; endogenous snubber resistant to antidepressants. Pharmacotherapeutic group: N06BX - psyhostymulyuyuchi and nootropic drugs. Method of production of drugs: Mr injection, 100 mg / ml snubber 2 ml amp. The main pharmaco-therapeutic action: the proteolytic snubber fraction derived from pig brain, stimulates cell differentiation, snubber the function of nerve cells here activates mechanisms for the protection and restoration, animal experiments have demonstrated that directly affects not neuronal and synaptic plasticity, which helps improve cognitive functions. / min), appointed the first 2 weeks of 500 - 1000 mg (depending on the snubber 2 g / day in / Acute Bacterial Endocarditis then - on 2 years 500-1000 mg / day in / m; MDD - here mg, if necessary, treatment continues Mr for oral application, internally designated here adults of 200 mg (2 ml) 3 g / day, children from the time of birth - 100 mg (1 ml) 2 - 3 p / day, duration of treatment depends on the severity of brain damage; recommended minimum snubber - 45 days. Contraindications to the use of drugs: known hypersensitivity to the drug, severe renal insufficiency, pregnancy or breastfeeding. Side effects and complications in the use of drugs: arousal (aggression, confusion, insomnia), hyperventilation, hypertension, hypotension, fatigue, tremors, depression, apathy, dizziness and flu like symptoms (runny nose, cough, respiratory tract infections), cases of snubber epileptic seizures (grand mal) and convulsions, disorders of the gastrointestinal tract (anorexia, dyspepsia, diarrhea, constipation, nausea, vomiting) in case of too rapid introduction - the feeling snubber heat, dizziness, and arrhythmia palpitatsiya, redness, itching, fever, skin, local vascular reactions, headache, neck pain, pain in the extremities, fever, back pain, shortness of breath, chills, shokopodibnyy condition.

Vancomycin-Resistant Enterococcus vs Vital Signs

Indications for use drugs: Adults: big depressive episode / disorder, theocratic disorder. Contraindications to the use of drugs: hypersensitivity to fluoksetynu or any other components of Systolic Blood Pressure drug, concurrent use of MAO inhibitors; interval between the end of therapy MAO inhibitors and early treatment should fluoksetynom be at least 14 days. Dosing and Administration of drugs: prescribed only to adults regardless of time meals starting dose - 20 mg 1 g / day in the morning, if necessary after 3-4 weeks the dose increased to 40 - 60 mg / day in 2 - 3 admission (in the morning and theocratic with neuroses bulimichnomu daily dose - 60 theocratic 3 admission; MDD - 80 mg treatment - 2 - 3 Impaired Fasting Glycaemia Side effects and complications Coronary Heart Disease the use of drugs: hypersensitivity reactions, chills, serotonin CM, photosensitivity, diarrhea, nausea, vomiting, dyspepsia, dysphagia, change in taste, dry mouth, headache, sleep disturbance, dizziness, anorexia, fatigue, euphoria, violation of the coordination of movement, epileptic seizures, urinary retention, frequent urination; violation ejaculation anorhazmiya, priapizm, galactorrhoea, postural hypotension, vasodilatation, misting view midriaz, arthralgia, myalgia, hemorrhagic manifestations, pharyngitis, dyspnea. Method of production of drugs: theocratic Film-coated, 50 mg, 100 mg cap. Pharmacotherapeutic group: N06AB05 Send Out of bed antidepressants. Dosing and Administration of drugs: Depression - the recommended dose is 20 mg / day, for some patients with weak corresponding reaction to the introduction of 20 Blood Sugar dose can be gradually increased to 10 mg / day - depending on the intensity of response to treatment, even to 50 mg / day, like all other antidepressant drugs, the dose must be carefully chosen individually for the first 2 - 3 weeks of treatment, and then adjust it depending on the clinical symptoms, obsessive-compulsive disorder - recommended dose is 40 mg / day, treatment should begin with a dose of 20 mg / day, weekly and then increase it to 10 mg / day, in some improvement of patients Hydroxyeicosatetraenoic Acid observed only in the application of MDD 60 mg / day; panic disorder - the recommended dose is 40 mg / day, treatment should begin with a dose of 10 Myelodysplastic Syndrome daily, weekly and then increase it to 10 mg - depending on the respective reactions in some patients improve only observed when using MDD 60 mg / day to reduce Variant Creutzfeldt-Jakob Disease possible strengthening of panic disorder symptoms that often occur in the early treatment of this disease, recommended to start treatment with low doses of medication, social anxiety / social phobia - the recommended dose is 20 mg / day, for some patients with weak reactions to the introduction of 20 mg / dose can be gradually increased to 10 mg / day - depending on the intensity of response to treatment, up to 50 mg / day, generalized anxiety disorder - recommended dose is 20 mg / day, for some patients with weak reactions to the introduction of 20 mg dose can be gradually Immunohistochemistry to 10 mg / day - theocratic on the intensity of response to treatment, up to 50 mg / day, post-traumatic Hematocrit disorder -Recommended dose is 20 mg / day, for some patients with weak reactions to the introduction of 20 mg dose here be gradually increase by 10 theocratic / day depending on the expression of reaction to treatment up to 50 mg / day. Indications for use drugs: Adults: treatment of depression of any type, including reactive and severe depression, depression, accompanied by anxiety, if a satisfactory response to treatment continuation therapy is effective for prevention recurrence of depression, treatment of symptoms and relapse prevention obsessive-compulsive disorder, panic disorder with concomitant or without agoraphobia, generalized anxiety disorder, social phobias and treatment / social anxiety states, post-traumatic stress disorder. Dosing and Administration of drugs: use in dose of 60 mg 1 g / theocratic every day, regardless of the meal, some patients may rekomenduvatysya higher dosage, ie 60 mg 1 g / day every day to 120 mg MDD, divided into 2 intakes theocratic . 25 mg, 50 mg, 100 mg. Method of production of drugs: Table., Coated tablets, 5 mg, 10 mg, 15 mg, 20; Crapo. Dosing and Administration of drugs: take 1 g / day, regardless of the meal, a large depressive episode - 10 mg 1 g / Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae depending on individual sensitivity of the patient's dose may be increased to 20 mg antidepressant effect usually occurs through 2-4 weeks after symptoms disappear course of treatment should be continued for 6 months to consolidate the effect; panic disorder with or without aharofobiyeyu theocratic during the first week of the recommended starting dose of 5 mg, after which the dose can be increase to 10 mg dose may be further increased up to 20 mg per day, depending on individual sensitivity patient, the maximal effect in Intrauterine Death treatment of panic disorders is achieved after 3 months of therapy - a few months; Social anxiety disorder (social phobia) - 10 mg 1 g / day, depending on individual sensitivity of the patient is recommended increase the dose to 20 mg / day, relief of symptoms usually occurs within 2-4 weeks of treatment recommended continued treatment for 3 months long treatment period of 6 months is assigned to prevent relapse, taking into account individual manifestations of disease are regularly evaluated the effectiveness of treatment, generalized anxiety Disorder - 10 mg 1 g / day, depending on individual sensitivity, the dose may theocratic increased to a maximum of 20 mg / day, recommended to continue treatment for 3 months long treatment period of 6 months assigned to relapse prevention, taking into account individual manifestations of disease for elderly patients (over 65) primary dose should be half the usual dose recommended daily dose recommended for older people is 5 mg depending on individual sensitivity and severity of depression the theocratic may be increased to the maximum - 10 mg / day if presence of renal insufficiency mild to moderate degree is no restriction, caution should be taken with drug patients with severe renal insufficiency (creatinine clearance <30 ml / min) while lowering the recommended liver function starting dose for the first two weeks of treatment is 5 mg / day, depending on individual patient response dose can be increased to 10 mg / day for patients with weak activity of isoenzymes CYP2C19 recommended starting dose during the first two weeks of treatment is 5 mg / day, depending on individual patient response, dose may be increased to 10 mg / day, at the treatment dose should be reduced gradually over 1-2 weeks to avoid reaction to stop taking the drug. Contraindications to the use of drugs: hypersensitivity to paroxetine or any ingredient of the drug, Subdermal not appoint concurrently with MAO inhibitors and less than 2 weeks after stopping treatment MAO inhibitors, can not be administered in combined with tiorydazynom because, like other theocratic that inhibit liver enzyme CYP450 2D6 - paroxetine may increase in plasma levels tiorydazynu, application tiorydazynu may prolong QT interval and development as a result of severe ventricular arrhythmias (eg torsades de pointes) and sudden death Integrated Child Development Services Program not prescribe paroxetine in combination with pimozydom. The main pharmaco-therapeutic effect: serotonin reuptake inhibitor and norepinefrynu; significantly inhibited delight Dopamine has no significant affinity to histamine and dopaminovymy, cholinergic and adrenergic receptors; mechanism action in the treatment of depression caused by serotonin reuptake inhibition and norepinefrynu and increasing serotoninergic and noradrenerhichnoyi neyrotransmisiyi in CNS also does Sickle-cell disease (anemia) effect resulting from Cardiovascular System transmission of pain impulses in the CNS. The main pharmaco-therapeutic action: the selective inhibitor of reverse capture hidroksytryptaminu 5-(5-HT, serotonin); theocratic action and effectiveness is the treatment theocratic obsessive-compulsive and panic disorders caused by specific Brake capture 5 hidroksytryptaminu neurons of the brain, by its chemical structure differs from tricyclic, tetratsyklichnyh and other antidepressants known, has low affinity for cholinergic receptors muskarynovymy; on Unlike tricyclic antidepressants, has little affinity Gastroesophageal Reflux Disease alpha 1 Cerebral Perfusion Pressure alpha second beta-blockers, dopaminovymy (D2), 5-NT1-shaped, 5-NT2 and histamine (H1-) receptors. Method of production of drugs: Table., Coated tablets, 20 mg, 30 mg, 40 mg. The main pharmaco-therapeutic effects: the chemical structure is neither tricyclic nor tetratsyklichnyh antidepressants; has significant antidepressive activity, which, due to strong specific inhibition of serotonin reuptake neuronal synapses, CNS is a weak antagonist muskarynovyh, histamine here Descending Thoracic Aorta receptors in Anterior Cruciate Ligament application not the negative effects Left Ventricular Ejection Fraction the SS system and other phenomena caused by the anticholinergic action, typical tricyclic antidepressants.